BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
BioAge Labs, Inc.NASDAQ: BIOA
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables declines year over year
Q1 FY2026 accounts payables of $326K fell 84.1% year over year, ahead of the -155.1% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -7.4% a year.
Context
- Accounts payables amounted to 8.8% of revenue in FY2025.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -84.1% holds above the trailing-twelve-month pace of -155.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 788K USD
- Year-over-year change
- +13033.3%
- 3-year CAGR
- -7.4%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 788K | +13033.3% |
| FY2024 | 2024-12-31 | 6K | +101.5% |
| FY2023 | 2023-12-31 | (393K) | -139.5% |
| FY2022 | 2022-12-31 | 994K | — |
Accounts Payables vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -155.1% is the 7th highest of 8, against a peer median of -67.8%.
- Accounts payables amounts to 9.0% of revenue for BIOA, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$8.05M CAD | -158.1% | +0.0% | 2.6% | |
| LTM Mar 2026 | $2.06M USD | +115.0% | — | — | |
| LTM Mar 2026 | $1.13M USD | +32.3% | — | 2.9% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $933K USD | -155.1% | -7.4% | 9.0% |
| LTM Mar 2026 | $734K USD | — | — | 0.5% | |
| LTM Mar 2026 | $310K USD | -132.7% | — | — | |
| LTM Mar 2026 | $232K USD | -67.8% | — | — | |
| LTM Mar 2026 | $60K USD | +361.5% | -6.3% | 0.1% | |
| LTM Mar 2026 | $42K USD | -102.6% | — | 2.1% | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| Peer median (excluding BIOA) | — | -67.8% | -3.2% | 1.3% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.